---
document_datetime: 2023-09-21 17:33:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/paxene-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: paxene-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.686119
conversion_datetime: 2025-12-27 14:54:15.886052
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 30 November 2004 please refer to module 8B.

- On  21  July  1999  the  Marketing  Authorisation  Holder  submitted  an  application  for  a  Type  I variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95.  The  scope  of  the variation  related  to  the  inclusion  of  an  additional  batch  size  of  the  finished  product.  This variation did not require any amendment  to  the terms of  the  Community  Marketing Authorisation.
- On  21  July  1999  the  Marketing  Authorisation  Holder  submitted  an  application  for  a  Type  I variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95.  The  scope  of  the variation related to a change in manufacturing site for part or all of the manufacturing process of the medicinal product. The EMEA approved the variation on 12 August 1999, which required amendments  to  be  incorporated  in  the  relevant  sections  of  the  Commission  Decision.  The European Commission amended the Decision on 5 October 1999.
- Pursuant  to  Article  4  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as amended, Norton Healthcare Limited submitted to the EMEA on 13 April 2000 an application for  a  Type  I  variation.  The  procedure  started  on  19  April  2000 . The  scope  of  the  variation related to a change of manufacturing site. This variation did not require any amendment to the terms of the Community Marketing Authorisation. The Notification was signed by the EMEA on the 15 May 2000. · Pursuant  to  Article  6  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as amended,  Norton  Healthcare  Limited  submitted  to  the  EMEA  on  9  November  1999  an application for a Type II variation. The procedure started on 19 November 1999. Supplementary information  was  supplied  by  the  Marketing  Authorisation  Holder  on  14  January  2000  and  a clarification on the supplementary information was supplied on 14 April 2000. The scope of the variation related to an application for the addition of a manufacturer of the active ingredient. This  variation  did  not  require  any  amendments  to  the  terms  of  the  Community  Marketing Authorisation. The EMEA approved the variation on the 25 May 2000. · Pursuant  to  Article   6  of  Commission   Regulation   (EC)  No   542/95  of  10   March   1995,  as amended, Norton Healthcare Ltd submitted to the EMEA on 15 June 2000 an application for a Type II variation. The procedure started on 30 June 2000. The scope of the variation related to amendment to section 4.8 of the SPC following the review of the first PSUR for Paxene. The EMEA  approved  the  variation  on  the  27  July  2000,  which  required  amendments  to  be incorporated in the relevant sections of the Commission Decision. The European Commission amended the Decision on 14 November 2000. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                        | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|----------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Update of Summary of Product Characteristics                                                 | II/06                | II                       | 18.10.01                            | 08.10.02                                 |
| Update of Summary of Product Characteristics (point 4.5)                                     | II/07                | II                       | 28.05.02                            | 08.10.02                                 |
| Extension of Indication                                                                      | II/08                | II                       | 21.01.04                            | 08.03.04                                 |
| Extension of Indication                                                                      | II/09                | II                       | 21.01.04                            | 08.03.04                                 |
| Quality changes                                                                              | II/10                | II                       | 21.01.04                            | 30.01.04                                 |
| Change in the batch size of finished product                                                 | I/11                 | I                        | 26.11.03                            | -                                        |
| New presentation(s)                                                                          | II/12                | II                       | 20.11.03                            | 20.01.04                                 |
| Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | IA/14                | IA                       | 26.03.04                            | -                                        |
| Minor change in the manufacturing process of the active substance                            | IB/16                | IB                       | 22.04.04                            | -                                        |
| Change in re-test period of the active substance                                             | IB/17                | IB                       | 14.04.04                            | -                                        |
| Change in the name and/or address of a manufacturer of the finished product                  | IA/18                | IA                       | 26.03.04                            | -                                        |
| Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing            | IA/19                | IA                       | 31.03.04                            | -                                        |
| Change in spec. of active subst./agent in manuf. of active subst. - test parameter           | IB/21                | IB                       | 19.07.04                            |                                          |
| Renewal                                                                                      | R/22                 | R                        | 29.07.04                            | 28.10.04                                 |
| Quality changes                                                                              | II/23                | II                       | 18.11.04                            | 25.11.04                                 |
| Replacement/add. of manufacturing site: Secondary packaging site                             | IA/29                | IA                       | 14.10.04                            | -                                        |
| Change in any part of primary packaging material not in contact with finished product        | IA/30                | IA                       | 11.10.04                            | -                                        |

<!-- image -->

Medicinal product no longer authorised

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.